Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
I would treat this as an urgent patient-safety and governance event, not as an earnings-management problem. A suspected fatal or life-threatening adverse effect affecting potentially hundreds of patients is sufficient to trigger immediate escalation, investigation, and regulator contact.Read the full answer
As CEO, I would not wait six months and I would not let the board delay disclosure while patients remain exposed to an unreported serious risk. I would treat this as a patient-safety, regulatory, legal, and trust crisis—not merely a financial-risk issue. My guiding decisions would be: Patient safety comes first.Read the full answer